In addition, in the postoperative prevention and treatment of HCC with high POSTN expression, the application of cilengitide combined with levastinib provides a feasible plan for clinical treatment (Chen et al., 2021). The gene discussed is POSTN; the disease is hepatocellular carcinoma.